دورية أكاديمية

Endoscopic postoperative recurrence in Crohn’s disease : after curative ileocecal resection with early prophylaxis by anti-TNF, vedolizumab or ustekinumab : a real-world multicentre European study

التفاصيل البيبلوغرافية
العنوان: Endoscopic postoperative recurrence in Crohn’s disease : after curative ileocecal resection with early prophylaxis by anti-TNF, vedolizumab or ustekinumab : a real-world multicentre European study
المؤلفون: Yanai, Henit, Kagramanova, Anna, Knyazev, Oleg, Sabino, João, Haenen, Shana, Mantzaris, Gerassimos J., Mountaki, Katerina, Armuzzi, Alessandro, Pugliese, Daniela, Furfaro, Federica, Fiorino, Gionata, Drobne, David, Kurent, Tina, Yassin, Sharif, Maharshak, Nitsan, Castiglione, Fabiana, de Sire, Roberto, Nardone, Olga Maria, Farkas, Klaudia, Molnar, Tamas, Krznaric, Zeljko, Brinar, Marko, Chashkova, Elena, Livne Margolin, Moran, Kopylov, Uri, Bezzio, Cristina, Shitrit, AriellaBar-Gi, Lukas, Milan, Chaparro, María, Truyens, Marie, Nancey, Stéphane, Lobaton, Triana, Gisbert, Javier P., Saibeni, Simone, Bacsúr, Péter, Bossuyt, Peter, Schulberg, Julien, Hoentjen, Frank, Viganò, Chiara, Palermo, Andrea, Torres, Joana, Revés, Joana, Karmiris, Konstantinos, Velegraki, Magdalini, Savarino, Edoardo, Markopoulos, Panagiotis, Tsironi, Eftychia, Ellul, Pierre, Suárez, Cristina Calviño, Weisshof, Roni, Ben-Hur, Dana, Naftali, Timna, Eriksson, Carl, Koutroubakis, Ioannis E., Foteinogiannopoulou, Kalliopi, Limdi, Jimmy K., Liu, Eleanor, Surís, Gerard, Calabrese, Emma, Zorzi, Francesca, Filip, Rafał, Ribaldone, Davide Giuseppe, Snir, Yifat, Goren, Idan, Banai-Eran, Hagar, Broytman, Yelena, Amir Barak, Hadar, Avni-Biron, Irit, Ollech, Jacob E., Dotan, Iris, Golan, Maya Aharoni
بيانات النشر: Oxford University Press
سنة النشر: 2022
المجموعة: University of Malta: OAR@UM / L-Università ta' Malta
مصطلحات موضوعية: Inflammatory bowel diseases, Crohn's disease, Biologicals, Endoscopy, Gastroenteritis
الوصف: Background: Endoscopic-post-operative-recurrence [ePOR] in Crohn’s disease [CD] after ileocecal resection [ICR] is a major concern. We aimed to evaluate the effectiveness of early prophylaxis with biologics and to compare anti-tumour necrosis factor [anti-TNF] therapy to vedolizumab [VDZ] and ustekinumab [UST] in a real-world setting. Methods: A retrospective multicentre study of CD-adults after curative ICR on early prophylaxis was undertaken. ePOR was defined as a Rutgeerts score [RS] ≥ i2 or colonic-segmental-SES-CD ≥ 6. Multivariable logistic regression was used to evaluate risk factors, and inverse prob ability treatment weighting [IPTW] was applied to compare the effectiveness between agents. Results: The study included 297 patients (53.9% males, age at diagnosis 24 years [19–32], age at ICR 34 years [26–43], 18.5% smokers, 27.6% biologic-naïve, 65.7% anti-TNF experienced, 28.6% two or more biologics and 17.2% previous surgery). Overall, 224, 39 and 34 patients received anti-TNF, VDZ or UST, respectively. Patients treated with VDZ and UST were more biologic experienced with higher rates of previous surgery. ePOR rates within 1 year were 41.8%. ePOR rates by treatment groups were: anti-TNF 40.2%, VDZ 33% and UST 61.8%. Risk factors for ePOR at 1 year were: past-infliximab (adjusted odds ratio [adj.OR] = 1.73 [95% confidence interval, CI: 1.01–2.97]), past-adalimumab [adj.OR = 2.32 [95% CI: 1.35-4.01] and surgical aspects. After IPTW, the risk of ePOR within 1 year of VDZ vs anti-TNF or UST vs anti-TNF was comparable (OR = 0.55 [95% CI: 0.25–1.19], OR = 1.86 [95% CI: 0.79–4.38]), respectively. Conclusion. Prevention of ePOR within 1 year after surgery was successful in ~60% of patients. Patients treated with VDZ or UST consisted of a more refractory group. After controlling for confounders, no differences in ePOR risk were seen between anti-TNF prophylaxis and other groups. ; peer-reviewed
نوع الوثيقة: article in journal/newspaper
اللغة: English
العلاقة: Yanai, H., Kagramanova, A., Knyazev, O., Sabino, J., Haenen, S., Mantzaris, G. J., . & Aharoni Golan, M. (2022). Endoscopic postoperative recurrence in Crohn’s disease after curative ileocecal resection with early prophylaxis by anti-TNF, vedolizumab or ustekinumab: a real-world multicentre European study. Journal of Crohn's and Colitis, 16(12), 1882-1892.; https://www.um.edu.mt/library/oar/handle/123456789/119955Test
DOI: 10.1093/ecco-jcc/jjac100
الإتاحة: https://doi.org/10.1093/ecco-jcc/jjac100Test
https://www.um.edu.mt/library/oar/handle/123456789/119955Test
حقوق: info:eu-repo/semantics/openAccess ; The copyright of this work belongs to the author(s)/publisher. The rights of this work are as defined by the appropriate Copyright Legislation or as modified by any successive legislation. Users may access this work and can make use of the information contained in accordance with the Copyright Legislation provided that the author must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the prior permission of the copyright holder.
رقم الانضمام: edsbas.7B07172F
قاعدة البيانات: BASE